PHILADELPHIA, November 12, 2012 – PwC announced today that Michael Swanick was appointed as Global Pharmaceutical and Life Sciences Industry leader succeeding Simon Friend. As the global practice leader, Swanick is responsible for the strategy and direction of the firm's multinational pharmaceutical, medical device and life sciences practice, which is comprised of approximately 4,700 industry dedicated professionals around the world.
A 28-year veteran of PwC, Swanick most recently held the position of PwC's U.S. Pharmaceutical and Life Sciences Leader and Global Tax Leader for the practice. He will continue to serve in this capacity, while taking on additional global responsibilities for the firm.
“Mike is uniquely qualified for this role having been at the forefront of this industry for nearly three decades while at PwC,” said David Levy, MD, Global Health Industries practice leader with PwC. “As the global environment for pharmaceutical and life sciences companies becomes increasingly complex with greater demand from regulators, payers, providers and consumers, we remain committed to helping clients navigate challenging market dynamics and working with them to develop new, innovative approaches to enable continued success in the marketplace.”
In his expanded role, Swanick also oversees the firm's capabilities around pharmaceutical and life sciences business strategy, mergers and acquisitions (M&A), research & development (R&D), manufacturing, supply chain, sales & marketing, corporate & financial strategy, risk management, compliance, information technology (IT) systems, intellectual property (IP) management and talent management.
Based in Philadelphia, Swanick joined the firm in 1984 and has been a tax partner for nearly 20 years. He has worked on tax consulting and compliance matters for international and domestic pharmaceutical and life science companies, as well as manufacturing and medical device companies. He was the lead author of the firm’s 2009 report, Pharma 2020: Taxing times ahead, which brought a tax perspective to an analysis of the complex forces impacting pharmaceutical and life sciences companies through 2020.
Earlier in his PwC career, Swanick was the partner-in-charge of international tax services, and served as the lead tax partner on numerous multinational tax clients. He spent three years in London where he led PwC’s U.S. corporate tax consulting group, and spent two years in Brussels advising publicly traded U.S. and European pharmaceutical companies on their business strategies. Swanick earned a bachelor’s degree in accounting from St. Joseph’s University in Philadelphia and a master’s degree in taxation from the Villanova University School of Law in Villanova, Pennsylvania.
For more information about PwC's pharmaceutical and life sciences industry group, visit: www.pwc.com/pharma
About PwC’s Pharmaceutical, Medical Device and Life Sciences Industry Group
PwC’s Pharmaceutical, Medical Device and Life Sciences industry group (www.pwc.com/us/pharma and www.pwc.com/us/medtech) is dedicated to delivering effective solutions to the complex strategic, operational and financial challenges facing pharmaceutical, biotechnology and medical device companies. We provide industry-focused assurance, tax and advisory services to build public trust and enhance value for our clients and their stakeholders. Follow PwC Health Industries at http://twitter.com/PwCHealth.
About the PwC Network
PwC firms help organizations and individuals create the value they’re looking for. We’re a network of firms in 158 countries with more than 180,000 people who are committed to delivering quality in assurance, tax and advisory services. Tell us what matters to you and find out more by visiting us at www.pwc.com.
© 2012 PricewaterhouseCoopers LLP, a Delaware limited liability partnership. All rights reserved. PwC refers to the US member firm, and may sometimes refer to the PwC network. Each member firm is a separate legal entity. Please see www.pwc.com/structure for further details.
The Hubbell Group, Inc.
Tel: +1 (781) 878-8882